ALBO
Price:
$44.15
Market Cap:
$915.89M
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A234...[Read more]
Industry
Biotechnology
IPO Date
2007-05-11
Stock Exchange
NASDAQ
Ticker
ALBO
According to Albireo Pharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -84.83%. This represents a change of 200.91% compared to the average of -28.19% of the last 4 quarters.
The mean historical ROE of Albireo Pharma, Inc. over the last ten years is -58.37%. The current -84.83% ROE has changed 45.33% with respect to the historical average. Over the past ten years (40 quarters), ALBO's ROE was at its highest in in the September 2021 quarter at 31.41%. The ROE was at its lowest in in the September 2022 quarter at -38.39%.
Average
-58.37%
Median
-60.68%
Minimum
-86.19%
Maximum
-37.41%
Discovering the peaks and valleys of Albireo Pharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 134.16%
Maximum Annual ROE = -37.41%
Minimum Annual Increase = -23.59%
Minimum Annual ROE = -86.19%
Year | ROE | Change |
---|---|---|
2021 | -86.19% | 31.26% |
2020 | -65.66% | -14.69% |
2019 | -76.97% | 104.70% |
2018 | -37.60% | 0.50% |
2017 | -37.41% | -15.44% |
2016 | -44.25% | -6.59% |
2015 | -47.37% | -23.59% |
2014 | -61.99% | 4.40% |
2013 | -59.38% | -11.23% |
2012 | -66.89% | 134.16% |
The current ROE of Albireo Pharma, Inc. (ALBO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-76.27%
5-year avg
-60.77%
10-year avg
-58.37%
Albireo Pharma, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Albireo Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Albireo Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Albireo Pharma, Inc.'s ROE?
How is the ROE calculated for Albireo Pharma, Inc. (ALBO)?
What is the highest ROE for Albireo Pharma, Inc. (ALBO)?
What is the 3-year average ROE for Albireo Pharma, Inc. (ALBO)?
What is the 5-year average ROE for Albireo Pharma, Inc. (ALBO)?
How does the current ROE for Albireo Pharma, Inc. (ALBO) compare to its historical average?